Almirall closes gap in product portfolio through commercialization agreement with MC2
Spanish dermatology company Almirall's purchase of European rights for MC2 Therapeutics-developed drug gives the company a much-needed treatment for patients suffering from mild or moderate psoriasis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Last week's license, collaboration and commercialization agreement between Spanish dermatology company Almirall and Danish pharmaceutical firm MC2 Therapeutics on European rights to the drug Wynzora closes a pipeline gap in Almirall's portfolio of treatments for patients with psoriasis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Almirall acquires rights to new psoriasis drug in Europe
For subscribers
.jpg&w=384&q=75)
